Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Overview

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Background

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions

Advanced Renal Cell Carcinoma
Advanced Soft Tissue Sarcoma
Advanced Thyroid cancer

Clinical Trials

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2

Completed

Posted: 2014/11/25

Sponsor:Washington Universit...

ID:NCT02300545

Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy

Completed

Posted: 2014/11/04

Sponsor:

Spanish Oncology Gen...

ID:NCT02282579

Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)

Phase 2

Terminated

Posted: 2014/10/31

Sponsor:

Spanish Oncology Gen...

ID:NCT02279576

Evaluation of Votrient in Angiosarcoma

Phase 2

Terminated

Posted: 2014/08/08

Sponsor:Heidelberg Universit...

ID:NCT02212015

Pazopanib Maintenance Phase II

Phase 2

Terminated

Posted: 2014/08/04

Sponsor:Ludwig-Maximilians -...

ID:NCT02207309

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

GSK and Novartis Complete $16 Billion Asset Swap Deal, Reshaping Both Companies' Strategic Focus

9 days ago

GlaxoSmithKline and Novartis have completed their $16 billion asset swap deal, with GSK exchanging its oncology portfolio for Novartis's vaccines business, while also creating a joint consumer healthcare venture.

FDA Breakthrough Therapy Status Emerges as Game-Changer for Oncology Drug Development

3 months ago

FDA's Breakthrough Therapy designation offers accelerated approval pathways for promising oncology drugs, potentially reducing development timelines to just 3 years and extending patent life.

Real-World Data Supports Efficacy of Opdivo Plus Yervoy in mRCC Treatment

4 months ago

A recent study highlights the real-world effectiveness of Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with intermediate- or poor-risk advanced metastatic renal cell carcinoma (mRCC), showing promising overall survival and progression-free survival rates.

Aurobindo Pharma's Biosimilar Bevqolva Receives MHRA Approval for Cancer Treatment

5 months ago

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured MHRA approval in the UK for Bevqolva, a biosimilar of bevacizumab, expanding cancer treatment options.

FDA Approves New Pazopanib Formulation for RCC and Soft Tissue Sarcoma

6 months ago

The FDA has approved a new 200 mg formulation of pazopanib tablets for advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy